| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
19,370,000 |
| Market
Cap: |
776.74(K) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.0401 - $1.8 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Aravive is a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of diseases, including cancer and fibrosis. Co.'s primary product candidate, batiraxcept, is a decoy protein that targets the GAS6-AXL signaling pathway. By capturing serum GAS6, batiraxcept starves the AXL pathway of its signal, potentially halting the biological programming that promotes disease progression. AXL receptor signaling plays a role in multiple types of malignancies by promoting metastasis, cancer cell survival, resistance to treatments, and immune suppression.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Perceptive Life Sciences Master Fund Ltd |
10% Owner |
– – • |
2016-12-30 |
4/A |
B |
$14.66 |
$1,041,641 |
I/I |
71,063 |
3,989,724 |
1.5 |
- |
|
| Perceptive Life Sciences Master Fund Ltd |
10% Owner |
– – • |
2016-12-30 |
4 |
B |
$14.66 |
$1,388,846 |
I/I |
94,750 |
4,013,411 |
1.5 |
- |
|
| Perceptive Life Sciences Master Fund Ltd |
10% Owner |
– – • |
2016-12-29 |
4 |
B |
$14.37 |
$680,589 |
I/I |
47,375 |
3,918,661 |
1.5 |
- |
|
| Westberg Paul |
Sr. VP, Corporate Development |
• – – |
2016-12-27 |
4 |
S |
$15.85 |
$5,722 |
D/D |
(361) |
44,600 |
|
- |
|
| Brumm Joshua T |
Chief Financial Officer |
• – – |
2016-12-27 |
4 |
S |
$15.85 |
$15,692 |
D/D |
(990) |
64,824 |
|
- |
|
| Westberg Paul |
Sr. VP, Corporate Development |
• – – |
2016-12-16 |
4 |
AS |
$15.00 |
$75,000 |
D/D |
(5,000) |
44,961 |
|
- |
|
| Westberg Paul |
Sr. VP, Corporate Development |
• – – |
2016-12-16 |
4 |
OE |
$1.27 |
$6,325 |
D/D |
5,000 |
49,961 |
|
- |
|
| Jennings Edmon R |
Director |
– • – |
2016-12-08 |
4 |
S |
$12.96 |
$19,433 |
D/D |
(1,500) |
7,700 |
|
- |
|
| Brumm Joshua T |
Chief Financial Officer |
• – – |
2016-12-07 |
4 |
S |
$13.25 |
$40,028 |
D/D |
(3,021) |
65,814 |
|
- |
|
| Ward Shane |
SVP, Legal and Compliance |
• – – |
2016-10-11 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
19,265 |
|
- |
|
| Westberg Paul |
Sr. VP, Corporate Development |
• – – |
2016-10-11 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
44,961 |
|
- |
|
| Hislop Colin |
Chief Medical Officer |
• – – |
2016-10-11 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
| Brumm Joshua T |
Chief Financial Officer |
• – – |
2016-10-11 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
68,835 |
|
- |
|
| Akkaraju Srinivas |
Director |
– • – |
2016-10-03 |
4 |
B |
$12.25 |
$7,000,005 |
I/I |
571,429 |
571,429 |
2.1 |
- |
|
| Edelman Joseph |
10% Owner |
– – • |
2016-09-28 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
3,871,286 |
|
- |
|
| Edelman Joseph |
10% Owner |
– – • |
2016-09-28 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,797,419 |
|
- |
|
| Varian John |
Director |
– • – |
2016-08-25 |
4 |
S |
$12.97 |
$20,755 |
D/D |
(1,600) |
7,600 |
|
- |
|
| Shepard Jay |
President and CEO |
• • – |
2016-08-22 |
4 |
S |
$12.88 |
$70,093 |
D/D |
(5,442) |
155,358 |
|
- |
|
| Westberg Paul |
Sr. VP, Business Development |
• – – |
2016-06-15 |
4 |
S |
$10.63 |
$7,707 |
D/D |
(725) |
34,961 |
|
- |
|
| Brumm Joshua T |
Chief Financial Officer |
• – – |
2016-06-15 |
4 |
S |
$10.63 |
$15,392 |
D/D |
(1,448) |
58,835 |
|
- |
|
| Akkaraju Srinivas |
Director |
– • – |
2016-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
6,900 |
11,475 |
|
- |
|
| Brumm Joshua T |
Chief Financial Officer |
• – – |
2016-05-20 |
4 |
S |
$7.87 |
$9,956 |
D/D |
(1,265) |
60,283 |
|
- |
|
| Greer R Scott |
Director |
– • – |
2016-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
4,625 |
29,700 |
|
- |
|
| Malik Shahzad |
Director |
– • • |
2016-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
4,625 |
9,200 |
|
- |
|
| Jennings Edmon R |
Director |
– • – |
2016-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
4,625 |
9,200 |
|
- |
|
258 Records found
|
|
Page 7 of 11 |
|
|
